Observational studies: Propensity score analysis of non-randomized data

International MS Journal

Volumn 16, Issue 3, 2009, Pages 90-97

  Trojano, Maria ^a   Pellegrini, F ^b   Paolicelli, D ^a   Fuiani, A ^a   Di Renzo, V ^a  

^a UNIVERSITY OF BARI   (Italy)

^b Consorzio Mario Negri Sud ^*  (Italy)

Author keywords

Multiple sclerosis; Observational study; Propensity score; Randomized controlled trial

Indexed keywords

BETA INTERFERON; NEUTRALIZING ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL STUDY; DISABILITY; DISEASE COURSE; DRUG EFFICACY; INTERMETHOD COMPARISON; METHODOLOGY; MULTIPLE SCLEROSIS; OBSERVATIONAL STUDY; PROBABILITY; RELIABILITY; SCORING SYSTEM; STATISTICAL ANALYSIS; SYSTEMATIC ERROR; VALIDITY; COMPARATIVE STUDY; EPIDEMIOLOGY; HUMAN; OBSERVATION; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIAS (EPIDEMIOLOGY); DISABILITY EVALUATION; HUMANS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OBSERVATION; PROPENSITY SCORE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 73349127042     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I. Clinical trials. Lancet 2001; 357: 373-380.
2. D'Agostino RB Sr, Kwan H. Measuring effectiveness: what to expect without a randomized control group. Med Care 1995; 33(4 suppl): AS95-AS105.
3. D'Agostino RB Jr, D'Agostino RB Sr. Estimating treatment effects using observational data. JAMA 2007; 297: 314-316.
4. Comber H, Perry IJ. Observational studies for intervention assessment. Lancet 2001; 357: 2141-2142.
5. McKee M, Britton A, Black N et al. Methods in health services research. Interpreting the evidence: choosing between randomised and non randomised studies. BMJ 1999; 319: 312-315.
6. Dobre D, van Veldhuisen DJ, DeJongste MJL et al. The contribution of observational studies to the knowledge of drug effectiveness in heart failure. Br J Clin Pharmacol 2007; 64: 406-414.
7. Black N. Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996; 312: 1215-1218.
8. MacMahon S, Collins R. Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. Lancet 2001; 357: 455-462
9. Feinstein AR: Clinical Biostatistics, London: Mosby, 1977; pp16-20.
10. Matthews DE, Farewell VT: Using and Understanding Medical Statistics, 2nd edn, revised. Basel: Karger, 1988.
11. Rochon PA, Gurwitz JH, Sykora K et al. Reader's guide to critical appraisal of cohort studies:1. Role and design. BMJ 2005; 330: 895-897.
12. Wolfe RA. Observational studies are just as effective as randomized clinical trials. Blood Purif 2000; 18: 323-326.
13. Reeves GK, Cox DR, Darby SC et al. Some aspects of measurement error in explanatory variables for continous and binary regression models. Stat Med 1988; 17: 2157-2177.
14. Bar-Oz B, Moretti ME, Mareels G et al. Reporting bias in retrospective ascertainment of drug-induced embryopathy. Lancet 1999; 354: 1700-1701.
15. Swan SH, Shaw GM, Schulman J. Reporting and selection bias in casecontrol studies of congenital malformations. Epidemiology 1992; 3: 356-363.
16. Klein-Geltink JE, Rochon PA, Dyer S et al. Readers should systematically assess methods used to identify, measure and analyze confounding in observational cohort studies. J Clin Epidemiol 2007; 60: 766-772.
17. Hennekens CH, Buring JE, Manson JE et al. Lack of effect of longterm supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-1149.
18. Ad Hoc Subcommittee of the Liaison Committee of the World Health Organization and the International Society of Hypertension. Effects of calcium antagonists on the risks of coronary heart disease, cancer and bleeding. J Hypertens 1997; 15: 105-115.
19. Nelson HD, Humphrey LL, Nygren P et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288: 872-881.
20. Normand SLT, Sykora K, Li P et al. Reader's guide to critical appraisal of cohort studies: 3. Analytical strategies to reduce confounding. BMJ 2005; 330: 1021-1023.
21. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
22. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984; 79: 516-524.
23. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-2281.
24. Rosenbaum PR. Propensity score. In: Encyclopedia of Biostatistics (Armitage P, Colton T, eds), Vol. 5 (Pri-Sph). New York: Wiley; 1998:3551-5.28.
25. Trojano M, Russo P, Fuiani A et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. Mult Scler 2006; 12: 578-585.
26. Trojano M, Pellegrini F, Fuiani A et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007; 61: 300-306.
27. D'Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med 1998; 17: 2265-2281.
28. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127(Part 2): 757-763.
29. Weitzen S, Lapane KL, Toledano AY et al. Principles for modeling propensity scores in medical research: a systematic literature review. Pharmacoepidemiol Drug Saf 2004; 13: 841-853.
30. Shah BR, Laupacis A, Hux JE et al. Propensity score methods give similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005; 58: 550-559.
31. Yanovitzky I, Zanutto E, Hornik R. Estimating causal effects of public health education campaigns using propensity score methodology. Eval Program Plann 2005; 28: 209-220.
32. Austin PC. The performance of different propensity score methods for estimating marginal odds ratios. Stat Med 2007; 26: 3078-3094.
33. Austin PC. The performance of different propensity-score methods for estimating relative risks. J Clin Epidemiol 2008; 61: 537-545.
34. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 2006; 98: 253-259.
35. Austin PC. Propensity-score matching in the cardiovascular surgery literature from 2004 to 2006: A systematic review and suggestions for improvement. J Thorac Cardiovasc Surg 2007; 134: 1128-1135.
36. Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-436.
37. Gum PA, Thamilarasan M, Watanabe J et al. Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis. JAMA 2001; 286: 1187-1194.
38. Kern LM, Powe NR, Levine MA et al. Association between screening for osteoporosis and the incidence of hip fracture. Ann Intern Med 2005; 142: 173-181.
39. Ko DT, Chiu M, Austin PC et al. Safety and effectiveness of drug-eluting stents among diabetic patients: a propensity analysis. Am Heart J 2008; 156: 125-134.
40. Paolicelli D, Lavolpe V, Pellegrini F et al. A post-marketing evaluation of the impact of neutralizing antibodies on the effectiveness of interferon beta in relapsing-remitting multiple sclerosis. Mult Scler 2008; 14: S24; 68.
41. Vukusic S, Confavreux C. Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci 2003; 206: 135-137.
42. Pittock SJ, Mayr WT, McClelland RL et al. Change in MS related disability in a population-based cohort. A 10-year follow-up study. Neurology 2004; 62: 51-59.
43. Trojano M, Pellegrini F, Paolicelli D et al. Real-life impact of early interferon-beta therapy in relapsing multiple sclerosis. Ann Neurol 2009 (in press)
44. Braitman LE, Rosenbaum PR.Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med 2002; 137: 693-695.
45. Rosenbaum PR. Discussing hidden bias in observational studies. Ann Intern Med 1991; 115: 901-905.
46. Lin DY, Psaty BM, Kronmal RA. Assessing the sensitivity of regression results to unmeasured confounders in observational studies. Biometrics 1998; 54: 948-963.
47. Rubin DB. The design versus the analysis of observational studies for causal effects: parallels with the design of randomized studies. Stat Med 2007; 26: 20-36.
48. Trojano M. Is it time to recognize the use of observational data to estimate treatment effectiveness in multiple sclerosis? Neurology 2007; 69: 1478-1479.